Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

References

• HøvdingGAcute bacterial conjunctivitisActa Ophthalmol200886517
   PubMed Web of Science ®Google Scholar
• TarabishyABJengBHBacterial conjunctivitis: a review for internistsCleve Clin J Med20087550751218646586
   PubMed Web of Science ®Google Scholar
• PichicheroMPBacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistanceClin Pediatr (Phila)20115071320724317
   PubMed Web of Science ®Google Scholar
• GoldeKTGardinerMFBacterial conjunctivitis in children: a current review of pathogens and treatmentInt Ophthalmol Clin201151859221897142
   PubMedGoogle Scholar
• American Academy of Ophthalmology Cornea/External Disease PanelPreferred Practice Pattern© GuidelinesConjunctivitis – Limited RevisionSan Francisco, CAAmerican Academy of Ophthalmology2011 Available from: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx?sid=9955f101-a94b-4f8f-a3c9-15d014f613b9Accessed June 6, 2012
   Google Scholar
• SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev20062CD00121116625540
   PubMedGoogle Scholar
• WeissAAcute conjunctivitis in childhoodCurr Probl Pediatr1994244118174390
   PubMedGoogle Scholar
• CavuotoKZutshiDKarpCLMillerDFeuerWUpdate on bacterial conjunctivis in South FloridaOphthalmology2008115515617572497
   PubMed Web of Science ®Google Scholar
• AdebayoAParikhJGMcCormickSAShifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear InfirmaryGraefes Arch Clin Exp Ophthalmol201124911111920532549
   PubMed Web of Science ®Google Scholar
• DuttaDColeNWillcoxMFactors influencing bacterial adhesion to contact lensesMol Vis201218142122259220
   PubMed Web of Science ®Google Scholar
• FleiszigSMEvansDJThe pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosaClin Exp Optom20028527127812366347
   PubMedGoogle Scholar
• FleiszigSMThe Glenn A. Fry award lecture 2005. The pathogenesis of contact lens-related keratitisOptom Vis Sci20068386687317164674
   PubMed Web of Science ®Google Scholar
• GreenMApelAStapeltonFRisk factors and causative organisms in microbial keratitisCornea200827222718245962
   PubMed Web of Science ®Google Scholar
• WillcoxMDPPseudomonas aeruginosa infection and inflammation during contact lens wear: a reviewOptom Vis Sci20078427327817435510
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Cornea/External Disease PanelPreferred Practice Pattern© GuidelinesBacterial keratitis – Limited RevisionSan Francisco, CAAmerican Academy of Ophthalmology2011 Available from: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx?sid=9955f101-a94b-4f8f-a3c9-15d014f613b9Accessed June 6, 2012
   Google Scholar
• LyczakJBCannonCLPierGBEstablishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunistMicrobes Infect200021051106010967285
   PubMed Web of Science ®Google Scholar
• ChoyMHStapeltonFWilcoxMDZhuHComparison of virulence factors in Pseudomonas aeruginosa strains isolated from contact lens and non-contact lens-related keratitisJ Med Microbiol200857Pt 121539154619018027
   PubMed Web of Science ®Google Scholar
• HazlettLDRole of innate and adaptive immunity in the pathogenesis of keratitisOcul Immunol Inflamm20051313313816019672
   PubMed Web of Science ®Google Scholar
• FriedlaenderMHProtzkoEClinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapyClin Ophthalmol2007131019668461
   PubMedGoogle Scholar
• BowmanLMSiEPangJArchibaldRFriedlanderMDevelopment of a topical polymeric mucoadhesive ocular delivery system for azithromycinJ Ocul Pharmacol Ther20092513313919284320
   PubMed Web of Science ®Google Scholar
• AkpekEKVittitowJVerhoevenRSOcular distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulationJ Ocul Pharmacol Ther20092543343919857105
   PubMed Web of Science ®Google Scholar
• SiECBowmanLMHosseiniKPharmacokinetic comparisons of bromfenac in DuraSite and XibromJ Ocular Pharmacol Ther2011276166
   PubMed Web of Science ®Google Scholar
• Bausch and Lomb IncorporatedBesivance™ (besifloxacin ophthalmic suspension) 0.6%: US prescribing information [online] Available from: http://www.besivance.com/site/cms/includes/assets/documents/Besivance-Full-Prescribing-Info.pdfAccessed June 14, 2012
   Google Scholar
• Bausch and Lomb IncorporatedBesifloxacin ophthalmic suspension 0.6% (Besivance): Canadian product monographVaughan, ONBausch & Lomb Incorporated2009
   Google Scholar
• KarpeckiPDepaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther20093151452619393842
   PubMed Web of Science ®Google Scholar
• TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin2009251159116919323612
   PubMed Web of Science ®Google Scholar
• McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology20091161615162319643483
   PubMed Web of Science ®Google Scholar
• SilversteinBEAllaireCBatemanKMGearingerLSMorrisTWComstockTLEfficacy and tolerability of besifloxacin 0.6% ophthalmic suspension administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, double-masked, vehicle controlled, parallel group study in adults and childrenClin Ther201133132621397770
   PubMed Web of Science ®Google Scholar
• DeLeonJSilversteinBEAllaireCBesifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and childrenClin Drug Investig201232303317
   Web of Science ®Google Scholar
• HaasWPillarCMTorresMMorrisTMSahmDFMonitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 surveillance studyAm J Ophthalmol2011152567574.e321652021
   PubMed Web of Science ®Google Scholar
• HaasWPillarCMZurenkoGELeeJCBrunnerLSMorrisTWBesifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteriaAntimicrob Agents Chemother2009533552356019506065
   PubMed Web of Science ®Google Scholar
• ProkschJWGranvilCPSiou-MermetRComstockTLPaternoMRWardKWOcular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJ Ocul Pharm Ther200925335344
   PubMed Web of Science ®Google Scholar
• CagleGDavisSRosenthalASmithJTopical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter studyCurr Eye Res198115235347341065
   PubMed Web of Science ®Google Scholar
• LeibowitzHMAntibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitisAm J Ophthalmol1991112Suppl 429S33S1928271
   PubMedGoogle Scholar
• Clinical and Laboratory Standards InstituteMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth editionCLSI document M07-A6Wayne, PACLSI2003
   Google Scholar
• Clinical and Laboratory Standards InstituteMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth editionCLSI document M07-A8Wayne, PACLSI2009
   Google Scholar
• Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing: Fourteenth Informational SupplementCLSI document M100-S14Wayne, PACLSI2004
   Google Scholar
• Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing: Sixteenth Informational SupplementCLSI document M100-S16Wayne, PACLSI2006
   Google Scholar
• Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing: Nineteenth Informational SupplementCLSI document M100-S19Wayne, PACLSI2009
   Google Scholar
• MurrayPRBaronEJJorgensenJHLandryMLPfallerMAManual of Clinical MicrobiologyWashington DCASM Press2007
   Google Scholar
• AbelsonMBHellerWShapiroAMfor the AzaSite Clinical Study GroupClinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trialAm J Ophthalmol200814595996518374301
   PubMed Web of Science ®Google Scholar
• GigliottiFHendleyJOMorganJMichaelsRDickensMLohrJEfficacy of topical antibiotic therapy in acute conjunctivitis in chidrenJ Pediatr19841046236266323667
   PubMed Web of Science ®Google Scholar
• RosePWHarndenABrueggemannABChloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trialLancet2005366374315993231
   PubMed Web of Science ®Google Scholar
• HwangDJSchanzlinDJRotbergMHA Phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitisBr J Ophthalmol2003871004100912881345
   PubMed Web of Science ®Google Scholar
• MichaudLEfficacy of besifloxacin in the treatment of corneal ulcerClinical and refractive optometry2011229093
   Google Scholar
• TurakaKPenneRBRapuanoCJGiant fornix syndrome: a case seriesOphthal Plast Reconstr Surg20122846
   Web of Science ®Google Scholar
• SandersMEMooreQCIIINorcrossEWComparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitisCornea201130839020847656
   PubMed Web of Science ®Google Scholar